ICUI - ICU Medical, Inc.

ICUI

$126.21 1.64 (-1.28%)

After Hours: $126.21 +0.00 (+0.00%)

Last updated: Apr 15, 2026 23:07

52-Week Range

$126.21

$107.00 $126.21 $160.29

Fundamentals Overview

ICU Medical, Inc. is in the middle of its 52-week range with low valuation, trading relatively flat today.

Valuation low

P/B 1.47 P/S 1.4

Profitability

Net margin 0%

Risk (Beta)

0.85 — in line vol

Earnings & growth

EPS $0.03 Rev +0.6% Profit -363.3% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 51% confidence Risk: Moderate Volatility — Beta 0.85. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B

Pressures (Sell):

3M vs S&P 500: -17.2% · 3M vs Healthcare sector: -10.4%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$3.12B

P/E (TTM)

N/A

EPS (TTM)

$0.03

Dividend Yield

N/A

52-Week Range

$107.00 - $160.29

Volume vs Avg

N/A

Beta

0.85

About

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLoc...

Sector: Healthcare

Headquarters: US

Employees: 15,000

IPO Date: Mar 1992

Website: www.icumed.com

Beta: 0.85 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: mixed. Current institutional positions: Buy: 1, Hold: 1, Market Perform: 2, Outperform: 6, Overweight: 18, Strong Buy: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-5.89; current price is $126.21. That’s a -104.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	N/A
PEG (TTM)	N/A
P/B (TTM)	1.47
P/S (TTM)	1.4
P/FCF (TTM)	34.82
Liquidity & enterprise
Current Ratio (TTM)	2.36
Quick Ratio (TTM)	1.13
Cash Ratio (TTM)	0.62
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	0.03%
Gross margin (TTM)	36.81%
Operating margin (TTM)	2.8%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ICUI.

Analyst Sentiment at a Glance

B Sentiment Mixed

Buy 1Hold 1Market Perform 2Outperform 6Overweight 18Strong Buy 2

2 upgrades, 2 downgrades

Price Target Consensus

Current $126.21

Median $179.00

Consensus $179.00

Low consensus $178.00

High consensus $180.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
Piper Sandler	maintain	Overweight	Overweight	2026-02-20
Keybanc	maintain	Overweight	Overweight	2026-02-20
Keybanc	maintain	Overweight	Overweight	2025-11-07
Piper Sandler	maintain	Overweight	Overweight	2025-11-07
Keybanc	maintain	Overweight	Overweight	2025-10-21
Piper Sandler	maintain	Overweight	Overweight	2025-09-10
Raymond James	maintain	Strong Buy	Strong Buy	2025-08-08
Raymond James	maintain	Strong Buy	Strong Buy	2025-05-09
Keybanc	maintain	Overweight	Overweight	2025-04-21
Needham	maintain	Hold	Hold	2025-04-08
Jefferies	upgrade	Hold	Buy	2024-12-11
Keybanc	maintain	Overweight	Overweight	2024-11-13
Keybanc	maintain	Overweight	Overweight	2024-10-15
Raymond James	maintain	Outperform	Outperform	2024-09-12
Keybanc	maintain	Overweight	Overweight	2024-08-08
Raymond James	maintain	Outperform	Outperform	2024-08-08
Raymond James	upgrade	Market Perform	Outperform	2024-06-17
Keybanc	maintain	Overweight	Overweight	2024-02-28
Keybanc	maintain	Overweight	Overweight	2023-05-09
Keybanc	maintain	Overweight	Overweight	2023-05-08
Raymond James	downgrade	Outperform	Market Perform	2022-11-08
Raymond James	downgrade	Outperform	Market Perform	2022-11-07
Keybanc	maintain	Overweight	Overweight	2022-08-09
Raymond James	maintain	Outperform	Outperform	2022-08-09
Raymond James	maintain	Outperform	Outperform	2022-08-08
Keybanc	maintain	Overweight	Overweight	2022-08-08
Raymond James	maintain	Outperform	Outperform	2022-08-07
Keybanc	maintain	Overweight	Overweight	2022-08-03
Keybanc	maintain	Overweight	Overweight	2022-08-02
Keybanc	maintain	Overweight	Overweight	2022-05-10